To focus on the launch of berdazimer gel 10.3%, Novan will be restructuring its commercial business and reducing its workforce due to profitability challenges, the company announced in a press release. “We continue to face serious challenges achieving profitability with our commercial assets in the current economic environment, while also endeavoring to extend our cash runway through the
Novan released its financial results for the first quarter of 2023, which included continued progress towards its prescription drug user fee act goal date for berdazimer gel 10.3%, according to a company press release. Novan announced its new drug application submission for berdazimer gel 10.3% for the treatment of molluscum contagiosum in January. The FDA accepted the application for filing and
15.05.2023 - – Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) – – Strong prescription growth across three promoted products – – Company to host conference call today at 8:30 a.m. ET – DURHAM, N.C., May 15, .
Operator: Hello and welcome to the Novan Inc. full year 2022 update conference call and webcast. As a brief reminder, all participants are currently in a listen-only mode.